Personal CFO Solutions LLC Purchases 6,643 Shares of Medtronic PLC $MDT

Personal CFO Solutions LLC raised its position in Medtronic PLC (NYSE:MDT) by 60.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,689 shares of the medical technology company’s stock after buying an additional 6,643 shares during the quarter. Personal CFO Solutions LLC’s holdings in Medtronic were worth $1,546,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Seelaus Asset Management LLC boosted its position in shares of Medtronic by 4.7% in the first quarter. Seelaus Asset Management LLC now owns 5,590 shares of the medical technology company’s stock valued at $484,000 after acquiring an additional 250 shares during the period. Farmers & Merchants Trust Co of Chambersburg PA raised its stake in Medtronic by 26.4% in the 1st quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 8,886 shares of the medical technology company’s stock worth $770,000 after purchasing an additional 1,858 shares in the last quarter. Frank Rimerman Advisors LLC boosted its holdings in Medtronic by 9.7% in the 1st quarter. Frank Rimerman Advisors LLC now owns 14,365 shares of the medical technology company’s stock valued at $1,245,000 after purchasing an additional 1,274 shares during the period. Quantum Portfolio Management LLC acquired a new position in shares of Medtronic during the 1st quarter worth approximately $423,000. Finally, Virginia Wealth Management Group Inc. increased its holdings in shares of Medtronic by 2.3% during the first quarter. Virginia Wealth Management Group Inc. now owns 34,235 shares of the medical technology company’s stock worth $2,966,000 after purchasing an additional 772 shares during the period. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

NYSE MDT opened at $82.06 on Thursday. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $105.04 billion, a price-to-earnings ratio of 22.00, a P/E/G ratio of 2.25 and a beta of 0.56. The firm’s 50 day simple moving average is $79.01 and its 200 day simple moving average is $88.67. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The business had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same period last year, the firm posted $1.62 earnings per share. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, research analysts expect that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.5%. The ex-dividend date is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio is 77.21%.

Analyst Ratings Changes

MDT has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Royal Bank Of Canada restated an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research note on Thursday, June 4th. Rothschild & Co Redburn dropped their price objective on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a report on Friday, June 5th. Barclays upped their target price on Medtronic from $118.00 to $120.00 and gave the company an “overweight” rating in a research report on Wednesday, April 1st. Finally, Sanford C. Bernstein reduced their target price on Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a report on Thursday, June 4th. Seventeen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $98.96.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).